TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03095391

Intervention type: DEVICE
Intervention: VFI
Description: The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.

Intervention type: DEVICE
Intervention: VFI
Description: The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.

Intervention type: DEVICE
Intervention: VFI
Description: The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.

Intervention type: DEVICE
Intervention: VFI
Description: The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.

Intervention type: DEVICE
Intervention: Iohexol
Description: Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.

Intervention type: DEVICE
Intervention: Iohexol
Description: Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.

Intervention type: DEVICE
Intervention: Iohexol
Description: Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
Study: NCT01909154

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cell therapy
Description: Stem cells administration locally
Study: NCT00862329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk soluble protein-enriched diet
Description: Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
Study: NCT04246060

Intervention type: DRUG
Intervention: Cysteamine Bitartrate
Description: ERT

Intervention type: DRUG
Intervention: Cysteamine Bitartrate
Description: ERT

Intervention type: DRUG
Intervention: Cysteamine Bitartrate
Description: ERT
Study: NCT01829516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal oxytocin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal placebo
Study: NCT00156533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: 10 mg of Zolpidem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: 10 mg of Zolpidem

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Study: NCT03577743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: -bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
Study: NCT00633347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agonist GnRH Acetate Triptoreline
Description: Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Agonist GnRH Acetate Triptoreline
Description: Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
Study: NCT02892760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Brace
Description: C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
Study: NCT04450147

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi/Qigong vs. Walking/Stretching
Description: Both interventions can be thought of as a form of movement and exercise.
Study: NCT04083209

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opioid counseling
Description: The formal opioid counseling will involve reading the recommendations for postoperative opioid use established by the Pennsylvania Orthopedic Society.
Study: NCT04027985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotaping
Description: inesio tape would be applied over the extensor muscles of the affected hand for facilitating the extension of hand. We will apply the tape from the upper 1/3 length of dorsal side of the forearm and split the tape into five equal bars to the distal interphalangeal joint of each finger along the finger bones. This intervention would be executed for five days per week for three weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hand rehabilitation program
Description: In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period.
Study: NCT00862329

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Casein and milk soluble proteins-enriched diet
Description: Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soy proteins-enriched diet
Description: Subjects consume for 9 days a supplement of 30g/d of soy protein
Study: NCT04027985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand rehabilitation program
Description: In the thirty-minute hand rehabilitation program, a motor-relearning theory would be implemented into the intervention by teaching the participants how to use their upper limb properly without any compensatory motions. Therefore, for establishing a correct movement pattern, an occupational therapist would provide a hand-guided activity, in which the participants could practice reaching movement as well as hand grasp and release in a more natural way. Besides, the therapist would also help the patients release their muscle tone by stretching the spastic muscles for five minutes before and after this hand rehabilitation period.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: A short piece of kinesio tape would be cut into half and applied over the lateral side of the forearm from the lateral epicondyle till the half of the forearm. The tape would not cover the both the flexor and extensor muscle bellies.
Study: NCT04794244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASGE-FABES Program
Description: In the control group study, pretest-posttest and experimental design with repeated measurements were used in randomized groups. An overweight and obese adolescent constituted the sample of 250 (125-experiment, 125-control) of the study. Research data Socio-Demographic Features Information Form, Adolescent Nutrition Information Scale, Adolescent Physical Activity Information Scale, Adolescent Lifestyle Scale, Healthy Lifestyle Choice Scale for Adolescents, Beck Anxiety Scale, Daily Food Consumption Form, Beverage Consumption Form, collected using. Data are saved before and after application. ASGEFABES PROGRAM was applied to the experimental group for 10 weeks. Measurements after the training program were collected in four measurements: 1st week, 6th and 12th months.
Study: NCT00439218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: 500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
Study: NCT04220983

Intervention type: RADIATION
Group type: OTHER
Intervention: MR-Guided Prostate SBRT
Description: Prostate SBRT has become a standard of care for the treatment of localized prostate cancer. Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity when planning is delivered appropriately.
Study: NCT00310037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study: NCT04680598

Intervention type: DRUG
Intervention: ICI
Description: Patients received ICI, including PD-1 inhibitor (pembrolizumab, toripalimab, nivolumab, sintilimab, camrelizumab) or PD-L1 inhibitor (atezolizumab)

Intervention type: DRUG
Intervention: ICI
Description: Patients received ICI, including PD-1 inhibitor (pembrolizumab, toripalimab, nivolumab, sintilimab, camrelizumab) or PD-L1 inhibitor (atezolizumab)

Intervention type: DRUG
Intervention: Antiviral Prophylaxis
Description: Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir

Intervention type: DRUG
Intervention: Antiviral Prophylaxis
Description: Patient received concurrent antiviral prophylaxis, such as tenofovir, entecavir
Study: NCT03431415

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anatomical Segmentectomy, Lobectomy or Bilobectomy
Description: Lung Cancer Anatomical Resection

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT treatment. 48Gy in 4 sessions for peripheral lesions and 50Gy in 5 sessions for central lesions.
Study: NCT03065166

Intervention type: OTHER
Group type: OTHER
Intervention: Raisin Treatment
Description: Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raisin Treatment
Description: Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.

Intervention type: OTHER
Group type: OTHER
Intervention: Bagel Control
Description: Subjects will consume 95g of whole wheat bagel during a single intervention time point.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bagel Control
Description: Subjects will consume 95g of whole wheat bagel during a single intervention time point.
Study: NCT03124524

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: estradiol valerate/dienogest
Description: oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinylestradiol and drospirenone
Description: oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
Study: NCT04249466

Intervention type: OTHER
Intervention: Questionnaire
Description: During this consult, several parameters will be measured :~* nutritional and physical activity parameters: Food Frequency Questionnaire (FFQ), International Physical Activity Questionnaire (IPAQ), Three-Factor Eating Questionnaire (TFEQ-R18), impedance test, anthropometric measurements, resting energy expenditure~* demographic and clinical parameters : Family history, date of birth (month and year), sex, genotype, best forced expiratory volume (FEV) (over the 12 months preceding inclusion), bacterial colonization~* patient treatment and biologic parameters: corticosteroid therapy (with dosage, over the 12 months preceding inclusion), antidiabetic treatment (oral or insulin), IV antibiotic treatment, corrective treatments, pancreatic enzymes, OGTT (blood glucose and insulin levels at three times), lipid balance, vitamin dosage.
Study: NCT04397757

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVID-19 Convalescent Plasma
Description: 2 units of COVID-19 convalescent plasma compatible with their blood type
Study: NCT03534466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Baby treadmill
Description: The newborns who received treadmill intervention were stimulated by running 3 times a week for a total of 10 minutes each time (complete in 5 cycles, 2 minutes per cycle, 2 minutes after the completion of one cycle and rest for 2 minutes to start the next cycle). Until the completion and completion of the five cycles). During the remaining four days of each week, other physical rehabilitation training is carried out by the rehabilitator in accordance with the established rehabilitation plan. The stimulation of running lasted from 3 months of corrected gestational age to being able to walk alone for 3 steps or to correct for 18 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Conventional physical rehabilitation training
Description: Suitable for general physical rehabilitation training of all infants with cerebral palsy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical rehabilitation training
Description: Suitable for general physical rehabilitation training of all infants with cerebral palsy.
Study: NCT03893994

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Stretching exercises will be applied 6 days a week, 30sec / 5 reps
Study: NCT02059174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1293
Description: MK-1293 0.4 units/kg administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1293
Description: MK-1293 0.4 units/kg administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-Lantus™
Description: EU-Lantus™ 0.4 units/kg administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EU-Lantus™
Description: EU-Lantus™ 0.4 units/kg administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog™
Description: Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novolog™
Description: Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
Study: NCT01768039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04371757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α1-adrenergic block
Description: Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α1-adrenergic block
Description: Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α1-adrenergic block
Description: Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an α-1 adrenoreceptor blocker (Drozazosin; 0.05 mg / kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Ninety minutes before starting the experimental exercise protocol, participants will be offered a capsule containing an placebo (microcrystalline cellulose; 0.05 mg.kg-1 body weight) and will be instructed to lie down. All capsules will be handled by a specialized pharmacy.
Study: NCT01309646

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix™-IPV+Hib
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix™ IPV
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™
Description: Intramuscular, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rotarix™
Description: Oral, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Oral, 2 doses
Study: NCT02143336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subcuticular suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin staples
Study: NCT03960593

Intervention type: OTHER
Intervention: Evaluation of the influence of geriatric factors
Description: Follow-up of patients\> 70 years old with cancer pathologies to evaluate the influence of geriatric factors associated with a review of therapies on their care pathways and health conditions. We will be particularly interested in the main objective, the unplanned hospitalization rate at 3 months in patients\> 70 years old with cancer treated in oncogeriatric HDJ before the initiation of oncological treatment such as chemotherapy (oral or intravenous) and / or targeted therapy and / or immunotherapy and / or new generation hormone therapy.
Study: NCT00792922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Comparison of community coverage rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Comparison of community coverage rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is \>5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is \>5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
Study: NCT03389659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: vitamin D3 400IU\*5pills po. qd continue to disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo 5 pills po. qd continue to disease progression
Study: NCT02246309

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embryoscope Time Lapse System
Description: The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Embryo Culture
Description: Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
Study: NCT01881724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep education
Study: NCT04134949

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: consists of eight weekly treatment sessions of 45 to 60 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: consists of eight weekly treatment sessions of 45 to 60 minutes.
Study: NCT03618433

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: study group
Description: The treatment protocol will consist of soft tissue massage, passive mobilization, stretching, self-stretching exercises. and shoulder proprioception .In addition to the standart exercise therapy, Kincet® video game program will be applied .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group included soft tissue massage, stretching, self-stretching, passive mobilization, coordination, posture exercises, progressive active and assisted shoulder exercises, proprioception and strengthening exercises in the exercise therapy protocol
Study: NCT03773016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Art apps
Description: Participants will be split into two groups of 6 participants; each group will use one app for two weeks and then change to the other app for another 2 weeks. Participants will be supported to use the app twice a week, with a maximum of 8 individual sessions over the four weeks. The intervention will be delivered to the participants at a quiet room in the care home by two co-investigators, one will be the facilitator, and the other one will be the observer. The intervention is a 30-minutes of individual sessions, with 10 minutes of app use. The additional 20 minutes will include the setup of the equipment and preparation of the participant at the beginning of the session; and questions for the participants at the end.
Study: NCT03106389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
Study: NCT00878189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03084014
Description: 10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
Study: NCT03106389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: 400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Misoprostol/Transcervical catheter
Description: Foleys' catheter introduced into the cervix and inflated with 30 ml. of fluid; weighted traction applied by using a 1000 ml fluid-filled bag